Altavo GmbH successfully raised €3 million in a Series A2 funding round to enhance its AI-driven voice rehabilitation technology for mute individuals.
Target Information
Altavo GmbH is a medical technology startup founded in February 2021, headquartered in Dresden, Germany. The company specializes in developing innovative solutions for voice rehabilitation through its proprietary AI-based artificial voice technology. This groundbreaking technology aims to restore natural-sounding voices to individuals who are voice-disabled due to conditions such as laryngectomy or reliance on artificial ventilation. Altavo's advancements are rooted in non-invasive radar sensing combined with cutting-edge AI algorithms, demonstrating its commitment to improving the quality of life for users.
With a team of 16 experienced employees in the fields of AI, data science, speech technology, high-frequency engineering, medical technology, and speech therapy, Altavo collaborates closely with the Technical University of Dresden. The company’s initiatives are supported under the SEMECO future cluster project “B3 / MUSIK”, which receives funding from both the Free State of Saxony and the European Union.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Germany
The medical technology industry in Germany is one of the largest in Europe, characterized by a strong emphasis on innovation and research. This sector contributes significantly to healthcare improvements, driven by
Similar Deals
Novalis Biotech and bm|t
invested in
Altavo GmbH
in 2026
in a Series A deal
Disclosed details
Transaction Size: $3M